Molecular Landscape of Alterations in 14,956 Solid Tumors.

abnormalities frequently occur and serve as rationale therapeutic targets in cancer. In this study, clinical and next-generation sequencing data from 14,956 patients across more than 20 tumor types were collected. A total of 406 (2.7%) patients were identified with amplifications, and 303 (2.0%) patients with pathogenic somatic mutations. amplifications fell most frequently in breast (15.9%) and stomach (8.3%) cancers. Somatic SNVs/indels occurred most common in bladder/urinary tract (7.3%) and intestine (6.1%) cancers. The top mutated SNVs/indels were p.Y772_A775dup (25.5%) and p.S310F/Y (19.9%). Significantly higher rates of SNV/indels were found in women compared to men (2.8% vs. 1.5%, < 0.0001). was the most common co-amplification gene with in cancers with a high frequency of amplifications. Patients with amplifications or mutations had higher TMB compared with patients with non- alterations. The study provided the landscape of alterations across a variety of solid tumors that may benefit from anti-HER2 agents.